- Home
- USEG vs OTLK Comparison
USEG vs OTLK Comparison
Compare USEG & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- OTLK
- Stock Information
- Founded
- USEG 1966
- OTLK 2010
- Country
- USEG United States
- OTLK United States
- Employees
- USEG N/A
- OTLK N/A
- Industry
- USEG Oil & Gas Production
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USEG Energy
- OTLK Health Care
- Exchange
- USEG Nasdaq
- OTLK Nasdaq
- Market Cap
- USEG 42.2M
- OTLK 48.3M
- IPO Year
- USEG N/A
- OTLK 2016
- Fundamental
- Price
- USEG $1.77
- OTLK $1.71
- Analyst Decision
- USEG Strong Buy
- OTLK Strong Buy
- Analyst Count
- USEG 2
- OTLK 5
- Target Price
- USEG $2.75
- OTLK $9.60
- AVG Volume (30 Days)
- USEG 8.2M
- OTLK 823.9K
- Earning Date
- USEG 08-06-2025
- OTLK 08-13-2025
- Dividend Yield
- USEG N/A
- OTLK N/A
- EPS Growth
- USEG N/A
- OTLK N/A
- EPS
- USEG N/A
- OTLK 0.83
- Revenue
- USEG $16,340,000.00
- OTLK N/A
- Revenue This Year
- USEG $23.82
- OTLK N/A
- Revenue Next Year
- USEG N/A
- OTLK $379.84
- P/E Ratio
- USEG N/A
- OTLK $2.06
- Revenue Growth
- USEG N/A
- OTLK N/A
- 52 Week Low
- USEG $0.81
- OTLK $0.87
- 52 Week High
- USEG $6.40
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- USEG 57.29
- OTLK 46.49
- Support Level
- USEG $1.65
- OTLK $1.65
- Resistance Level
- USEG $2.43
- OTLK $1.97
- Average True Range (ATR)
- USEG 0.25
- OTLK 0.12
- MACD
- USEG 0.06
- OTLK -0.03
- Stochastic Oscillator
- USEG 35.78
- OTLK 10.94
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.